by DIANNE JACOBS THOMPSON (under
1979 Around January of that year, I went
home to die.
I was diagnosed with stage 2 stomach cancer, chronic bronchitis,
acutely infected ovarian cysts, arthritis, sciatica, low thyroid,
anemia and a heart condition. Besides that I had chronic ear infections
and long-standing clinical depression. The late Dr.
Harold Dick, N.D., known as a "naturopathic oncology pioneer"
cured me in 5 weeks. It required the diagnosis (the Carroll
Food Test) of digestive enzyme
deficiency food intolerances which most people have and few
know about, and it also identified the primary tissue
salt deficiency, along with treatment with glandular
protomorphogens to restore glandular health, and Constitutional
Hydrotherapy to bring about detoxification, to stimulate blood
circulation and the activity of the vital organs and to jump-start
the immune system. It turned out to be the basic foundation of the
most successful healing system I've ever witnessed.
1986 My 5-year-old daughter was forcibly vaccinated
and immediately developed a flesh-eating
infection so virulent that my husband and I became infected
from contact. Naturopathic medicine brought us back from the brink.
Later that year
we were introduced to escharotic
cancer salves and treated a dog tumor, my husband's cirrhosis
of the liver, various skin lesions, moles, fungal infections, and
a lump in my thigh. It eventually
helped clear up the remaining symptoms from my husband's flesh-eating
infection after he was forced to submit to antibiotic treatment
which made a mess of it. There was much more, gallbladder
problems in 1999, adrenal
deficiency 2001, injury in 2002, arthritis,
diabetes, and other issues between
2003-2012, including glaucoma--cured.
why I research and write about alternative medicine. It's a debt.
Vaccine Reactions--Purpura , Ecchymoses, Thrombocytopenia
vaccines include fever, irritability,
loss of appetite, sleepiness and
inconsolable crying. (22)
Vaccines have also been shown to possibly produce more concerning
symptoms such as purpura, ecchymosis, thrombocytopenia
and other conditions that cause brain
44, 45, 46) or increased intracranial pressure
(47, 48, 49) in
a recognized percentage of children.(50)"
Purpura--any of several hemorrhagic states characterized
by patches of purplish discoloration resulting from extravasation of
blood into the skin and mucous membranes —see THROMBOCYTOPENIC
the purple or black-and-blue area resulting from a bruise
2. the escape of blood from ruptured blood vessels into the surrounding
tissue to form a purple or black-and-blue
spot on the skin
decrease in the number of blood platelets that is often associated with
hemorrhagic conditions called also thrombopenia —throm·bo·cy·to·pe·nic
HEPATITIS B VACCINATION AND INFANTILE IDIOPATHIC
SUMMARY: Since 1993, Iranian infants have
been routinely vaccinated against hepatitis B. In the period of 1993-2002,
twenty five children with infantile thrombocytopenic purpura
(ITP) were admitted to the Childrens Medical Center in Tabriz, Iran
whereas between 1982 and 1992, only two cases were hospitalized with
the same diagnosis. This suggests a cause and effect relationship between
hepatitis B vaccination and ITP.
ITP is an autoimmune disorder leading to a reduction of the number of
peripheral blood platelets (1). For reasons not well understood, autoantibodies
are generated against glycoproteins GpIb/Ix and GpIIb/IIIa and are stiuated
on the surface of the platelets. Attachment of autoantibodies to these
surface antigens leads to phagocytosis or
complement-induced lysis of the platelets involved. This process may
also involve megakaryocytes, leading to a decrease in platelet production
(2,4). Autoantibodies against platelet surface antigens have been detected
in 75% of the patients (2,3).
ITP appears in two forms: acute or chronic. The acute form occurs predominantly
in children. 85% of cases are preceded by a viral infection. The disorder
may last for one or two months period and is self limited. Mumps, measles,
rubella vaccine (MMR) has been implicated in the etiology of ITP (5-10).
In Finland, 23 cases of ITP were reported among 70.000 MMR vaccines.
The authors speculated that the vaccine leads to generation of antiplatelet
antibodies (1). In another study, one case of ITP was recorded among
24.000 MMR vaccines (10).
Occurrence of ITP following DPT vaccination is rare. In a British study,
only two cases were reported (8), this data is not significant when
the widespread administration of
DPT vaccine is considered. Two cases of ITP have been reported in conjunction
with small pox vaccination (12). Small numbers of cases following recombinant
been reported (13). There is no report of ITP following plasma-derived
hepatitis vaccine (11).
MATERIALS AND METHODS
ITP cases between 1992 and 2002
The files of all 25 infants under six months of age, hospitalized at
the Childrens Medical Center in Tabriz, Iran, between 1993 and 2002
and discharged with ITP as the final diagnosis were included in the
present study. The diagnosis was established based on the clinical findings
(purpura, ecchymosis), platelet count, bone marrow findings and exclusion
of other causes.
*From Department of Pediatrics, Tabriz University of Medical
Sciences, Tabriz, Iran.
Medical Journal of Islamic World Academy of Sciences 15:4, 149-151,
purpura and MMR vaccine E Millera, P Waighta, C P Farringtonb, N Andrewsa,
J Stowec, B Taylorc
a Immunisation Division,
Public Health Laboratory Service Communicable Disease Surveillance Centre,
Colindale, London NW9 5EQ, UK, b Department of Statistics, The Open
University, Milton Keynes MK7 6AA, UK, c Royal Free Campus, Royal Free
and University College Medical School, University College London, London
NW3 2PF, UK
Dr Miller firstname.lastname@example.org
Accepted 11 April
A CAUSAL ASSOCIATION BETWEEN MEASLES---mumps-rubella (MMR) vaccine and
idiopathic thrombocytopenic purpura (ITP) was confirmed using immunisation/hospital
admission record linkage. The absolute risk within six weeks of immunisation
was 1 in 22 300 doses, with two of every three cases occurring in the
six week post-immunisation period being caused by MMR.
1: Br J Clin
Pharmacol. 2003 Jan;55(1):107-11.
MMR vaccine and idiopathic thrombocytopaenic purpura.
Black C, Kaye JA, Jick H.
Department of Public
Health, Aberdeen University, Aberdeen, UK. email@example.com
AIMS: To estimate
the relationship between idiopathic thrombocytopaenic purpura (ITP)
and the measles, mumps and rubella (MMR) vaccination in children; calculating
the relative risk estimate for ITP with in 6 weeks after MMR vaccination
and the attributable risk of ITP within 6 weeks after MMR vaccination.
METHODS: Using the General Practice Research Database we identified
children with a first-time diagnosis of ITP from a base population of
children aged less than 6 years between January 1988 and December 1999.
After describing the characteristics of all the children identified
with ITP, we focused on cases aged 13-24 months to perform a population-based,
case-control analysis to estimate the relative risk of developing ITP
within 6 weeks after MMR vaccination. We also calculated the risk of
ITP attributable to the MMR vaccination. RESULTS: Sixty-three children
with a first time diagnosis of ITP were identified; 23 cases were between
13 and 24 months old. The relative risk estimate for ITP within 6 weeks
after MMR vaccination, compared to the combined group of unvaccinated
children and children vaccinated with MMR more than 26 weeks previously
was 6.3 (95% CI 1.3-30.1). The attributable risk of developing ITP within
6 weeks after MMR vaccination was estimated to be 1 in 25,000 vaccinations
(95% confidence interval 21,300, 89,400). CONCLUSION: This study confirms
the increased risk of ITP within 6 weeks after MMR vaccination. However,
the attributable risk of ITP within 6 weeks after MMR vaccination is
[PubMed - indexed for MEDLINE]
Acute immune thrombocytopenic purpura in infants: associated
factors, clinical features, treatment and long-term outcome
Authors: Wang, Jiaan-Der; Huang, Fang-Liang1; Chen, Po-Yen2;
Wang, Teh-Ming3; Chi, Ching-Shiang1; Chang, Te-Kau1
Source: European Journal of Haematology, Volume 77, Number
4, October 2006 , pp. 334-337(4)
Wang J-D, Huang F-L, Chen P-Y, Wang T-M, Chi C-S, Chang T-K. Acute immune
thrombocytopenic purpura in infants: associated factors, clinical features,
treatment and long-term outcome.
The natural course
of acute immune thrombocytopenic purpura (ITP) in infants is poorly
described in the literature. A retrospective study of 17 consecutive
patients <1?yr of age admitted and treated for acute ITP between
1996 and 2005 was conducted. We investigated their demographics, vaccination
history, clinical features, laboratory examinations, response to treatment
and long-term outcome. There were 11 male and six female infants. Their
ages ranged from 24?d to 12?months with a median of 3?months.
All infants presented with petechiae and/or ecchymoses.
Fourteen cases had platelet counts below 20?×?109/L at the time
of admission. They all had good response to a single course of treatment
(14/17) or multiple courses of treatment (3/17). None had progressed
into chronic ITP. Seven infants had a causal relationship
with immunization, five associated with
hepatitis B, one diphtheria-pertussis-tetanus,
one diphtheria-tetanus-acellular pertussis-inactivated
poliovirus vaccine-conjugated Haemophilus influenza vaccines.
These seven infants responded to treatment within 3-9?d after therapy
with intravenous immunoglobulin, high-dose methylprednisolone or oral
steroids. Re-boosters with vaccines revealed no recurrence of the disease
in all of these seven patients. The study suggests that further immunization
is not contraindicated in infants experiencing acute
ITP associated with vaccines.